Board of Directors

Board member since: 2019, member of the Audit and Remuneration Committees.

Born: 1967

Nationality: Swedish

Education: MBA Stockholm School of Economics.

Other assignments: Chairman of Mabtech AB. Board member of Surgical Science, Swedencare and Boule Diagnostics.

Experience: CEO of Investor Growth Capital, Chairman of Biotage AB and Swedish Orphan International AB.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Board member since: 2020, member of the Remuneration Committee.

Born: 1960

Nationality: Swedish

Education: Degree in Journalism from the University of Gothenburg.

Other assignments: Board member of Camurus AB (publ), Moberg Pharma AB (publ).

Experience: More than 30 years of experience from the international, pharmaceutical industry. Responsible for business development and corporate strategy as EVP at Nycomed, leading positions in marketing and business development at Astra and AstraZeneca.

Independent of the company  and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Board Member since: 2021

Born: 1967

Nationality: British

Education: BSc, Hons Pharmacology, University College London.

Other assignments: Chair of Resolution Therapeutics Ltd, Board Member of Ascendis Pharma AS, Dechra Pharmaceuticals Plc, Acacia Health Ltd. Advisor at Syncona Ltd and DRI Capital. Trustee at Centre for Disease Analysis Foundation.

Experience: President International and Chief Commercial and Corporate Affairs Officer for Intercept Pharma ceuticals Inc., Senior roles at Gilead Sciences including VP Head Inter national Government Affairs, VP Head International Launch Planning HCV, and VP Head Northern Europe. Senior roles at GSK plc and Sanofi.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Board member since: 2018

Born: 1974

Nationality: Swedish

Education: MD, Uppsala University, Registered physician; BSc, Inter national Economics and Business Administration, Uppsala University.

Other assignments: Board Member: Egetis Therapeutics AB (publ), TTM Holdco AB; Vlast AB; Greblaw AB; Board member and CEO: Cetoros AB. Board Member Akriam Therapeutics AB. 

Experience: Medical Doctor, St Görans Hospital and Uppsala University Hospital; Strategy Consultant, Boston Consulting Group; Head of New Products and BD&L, Novartis Nordics; EVP Head of Business Development and Strategy, Swedish Orphan International and Sobi; Founder and CEO, Medical Need Europe; Co founder, Wilson Therapeutics; Founder and CEO, Rare Thyroid Therapeutics;

Previous Board assignments: Wilson Therapeutics AB, OxThera AB.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Board member since: 2021, member of the Audit Committee.

Born: 1960

Nationality: Swedish

Education: Medical doctor, PhD, Assoc Professor.

Experience: Associate Dean of the Karolinska Institutet, The Boston Consulting Group 1996–2021.

Independent of the company  and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Board member since: 2017, member of the Remuneration Committee.

Born: 1979

Nationality: Swedish

Education: MSc Industrial Management & Engineering.

Other assignments: BoD Member Mallax Pharmaceuticals, Lowenco, Tandlaegen.dk, Vaccin Direkt, Avia Pharma, Impilo AB.

Experience: 15 years in private equity investing (Altor 2009–2017, Impilo 2017- current), 5 years in consulting in Boston Consulting Group (2004- 2009). Prior member of the BoD of NutraQ and Orchid Orthopedics.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Deputy board member since: 2018, member of the Audit Committee.

Born: 1987

Nationality: Swedish

Education: MSc Finance from London School of Economics, BSc Economics from University of Warwick, Graduate of the Swedish Armed Forces’ Language School.

Other assignments: Board member of Texray AB.

Experience: Investment Director at Impilo. Joined Impilo in 2017, prior to that Investment Professional at XIO Group (201517) and Investment Banking Analyst at Bank of America Merrill Lynch (201315).

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No